New immune cell combo targets hard-to-treat breast cancer
NCT ID NCT03272334
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment for women with metastatic breast cancer that has spread. It combines specially trained immune cells (HER2 BATs) that attack cancer cells with a drug called pembrolizumab that helps the immune system work better. The goal is to find a safe dose and see if the combination can shrink tumors. About 22 women will take part in two phases.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ashley Donihee
Charlottesville, Virginia, 22908, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug attack shrink Hard-to-Treat breast cancer?
- Can mapping tumor DNA unlock personalized breast cancer care?
- Could a personal coach at home boost energy for cancer patients?
- Can an immune booster help chemotherapy fight metastatic breast cancer?
- Can a Four-Drug cocktail tame a tough breast cancer?
- Can a new drug outsmart resistant breast cancer?